CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
November 2015—Illumina has launched TruSight Tumor 15, a next-generation sequencing panel designed to identify sequence variants in 15 genes commonly associated with marketed therapeutics. The sequencing panel is optimized for damaged and degraded formalin-fixed, paraffin-embedded tumor samples, enabling low frequency somatic variant detection from limited nucleic acid inputs. When paired with the Illumina MiSeq system, the panel delivers high-quality sequencing with key content and features needed for tumor analysis in translational research. Its streamlined multiplex PCR-based library prep method, with limited hands-on time, produces high-quality data in approximately 36 hours from extracted DNA to result. For research use only; not for use in diagnostic procedures.
Illumina, 858-202-4500